Module 3: When the In Vitro Micronucleus Is Positive: What It Means and How to Move Forward
Recorded On: 04/22/2027
This presentation provides an overview of the steps to take when navigating a positive or equivocal in vitro micronucleus test result, including how to utilize relevant regulatory guidance to guide data interpretation and follow-up strategies. The presentation covers how to assess the biological relevance of a positive result and evaluate potential nongenotoxic contributing factors. Methodological approaches to determine the mechanism of action are discussed, including approaches to distinguish between clastogens and aneugens, as well as how to determine potential nonlinear safety thresholds. A real-world case study is shared to illustrate how to address conflicting in vitro and in vivo results within a regulatory submission and strategic decision making to get a program back on track.
Sucheta Mukherjee, PhD, DABT
Principal Scientist - Toxicologist
Genentech, Inc.
Dr. Sucheta Mukherjee is a board-certified Principal Scientist - Toxicologist at Genentech, Inc., where she designs and oversees nonclinical toxicology programs for small molecule, large molecule, and oligonucleotide discovery and development in oncology, neuroscience, immunology, and ophthalmology indications. She previously worked at Aligos Therapeutics, Inc. (2019–2023) as a project toxicologist for small molecule and oligonucleotide programs focused on liver diseases. She received her doctorate in Pharmacology/Toxicology from the University of California, Davis in 2015 and was a DoD Horizon Award postdoctoral fellow at the University of California, San Francisco from 2016–2019. Dr. Mukherjee has been a member of ACT since 2020, where she served on the Early Career Professionals Subcommittee (ECPSC) from 2020–2023 and is currently serving as an elected member of the Education Committee (EdCom; 2025–present). Within ACT, she co-chaired one annual meeting session in 2021, co-hosted two ECP webinars on IND submissions (2021) and communication for toxicologists (2022), and was a panelist in a 2023 leadership webinar. In 2023, she co-led a mentorship focus group as part of the existing ACT mentorship platform on InterACT as well as outreach initiatives for member and non-member ECPs. As a part of EdCom, she contributes to the planning and implementation of all ACT educational opportunities including the Continuing Education (CE) program for the Annual Meeting, classroom-based courses, online courses, webinars, and podcasts. She is also actively involved in the Northern California Regional Chapter of SOT. She served as Treasurer from 2021–2023 and currently serves as Past President (as a part of the presidential chain; 2023–present), providing guidance to the NorCal SOT Board of Directors as they plan symposia and career development opportunities for the membership, which encompasses toxicologists from academia, CROs, industry, and government. Dr. Mukherjee is also an active member of the IQ DruSafe RNA Therapeutics Working Group curating surveys, presentations and publications for nonclinical strategies for oligonucleotide drug development. Dr. Mukherjee has co-authored nine publications and presented her work at ACT and SOT as well as several other national conferences, but her interest in genetic toxicology stems all the way back to her undergraduate research days studying mechanisms of DNA damage response.